After being diagnosed with a rare disease—indolent systemic mastocytosis (ISM)—and starting on a treatment that has reduced her ISM symptoms, she continues to adapt and is inspired to help ...

Later, the drug’s label was expanded by respective regulatory authorities in both geographies to treat advanced and indolent systemic mastocytosis (SM). In the press release, BPMC has updated ...

Later, the drug’s label was expanded by respective regulatory authorities in both geographies to treat advanced and indolent systemic mastocytosis (SM). In the press release, BPMC has updated its ...

Leerink Partners analyst Thomas Smith has reiterated their neutral stance on ALLK stock, giving a Hold rating on January 27.Invest with ...

In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Hold rating on Allakos (ALLK – Research Report), with a price ...

Growth in 2025 is expected to be fuelled by Ayvakit sales, which is approved for gastrointestinal stromal tumors and advanced and indolent systemic mastocytosis (SM). Per BPMC, the SM franchise has a ...

in patients with indolent systemic mastocytosis (ISM). Blueprint is advancing CDK2 and CDK4 targeted protein degraders, which have progressed faster than expected in preclinical development toward ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price target upped by equities research analysts at JPMorgan ...

Learn more about whether Blueprint Medicines Corporation or Zai Lab Limited is a better investment based on AAII's A+ ...